Clinical Trial Update: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating Aumolertinib with chemotherapy or as monotherapy compared to Osimertinib in EGFR-mutant non-small cell lung cancer has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: EQRx International, Inc. | Conditions: NSCLC | Phase 3 | Status: TERMINATED | Results posted: 2024-05-02